Background: Selenium (Se) is of importance for regular functioning of the immune system and thyroid gland, and may have a health effect in mild Graves' ophthalmopathy (GO).
Objective: As the Se status declines in inflammation, we analyzed whether GO activity or severity affects the Se status of patients.
Methods: Serum Se and selenoprotein P (SePP) concentrations were retrospectively determined in 84 consecutive GO patients before treatment and compared to their clinical activity score (CAS) and severity of eye changes (NOSPECS) status, and to the concentrations of autoantibodies targeting the TSH receptor (TRAK) or the IGF1 receptor (IGF1R-aAB).
Results: Serum Se and SePP were linearly associated, indicating a suboptimal Se status of our patients. In comparison to data from other European cohorts, the majority of GO patients had a relatively poor Se status ([Se] ± SD; 70.0 ± 23.8 µg/l), below the threshold needed for full expression of selenoproteins. TRAK were inversely associated with Se concentrations, while IGF1R-aAB titers were not associated with Se. Neither Se nor SePP concentrations differed between GO patients with severe versus mild or active versus inactive disease, or showed significant associations with the CAS or NOSPECS values.
Conclusion: GO patients are at risk of a low Se status, yet disease severity or activity does not seem to affect Se or SePP concentrations directly. However, as the retrospective nature of the analysis does not allow conclusions on a potential causative role of Se on Graves' disease or GO risk, these results neither support nor discourage adjuvant Se supplementation attempts.
Keywords: Autoimmunity; Exophthalmos; Graves’ disease; Selenoprotein P; Thyroid.
Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.Clin Endocrinol (Oxf). 2004 Nov;61(5):612-8. doi: 10.1111/j.1365-2265.2004.02143.x. Clin Endocrinol (Oxf). 2004. PMID: 15521965
Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.Korean J Ophthalmol. 2015 Aug;29(4):213-9. doi: 10.3341/kjo.2015.29.4.213. Epub 2015 Jul 21. Korean J Ophthalmol. 2015. PMID: 26240504 Free PMC article.
Serum selenium and selenoprotein-P levels in autoimmune thyroid diseases patients in a select center: a transversal study.Arch Endocrinol Metab. 2017 Dec;61(6):600-607. doi: 10.1590/2359-3997000000309. Arch Endocrinol Metab. 2017. PMID: 29412385
Selenium supplementation in thyroid associated ophthalmopathy: an update.Int J Ophthalmol. 2014 Apr 18;7(2):365-75. doi: 10.3980/j.issn.2222-3959.2014.02.31. eCollection 2014. Int J Ophthalmol. 2014. PMID: 24790886 Free PMC article. Review.
Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management.J Ophthalmol. 2015;2015:249125. doi: 10.1155/2015/249125. Epub 2015 Aug 17. J Ophthalmol. 2015. PMID: 26351570 Free PMC article. Review.
Cited by 10 articles
A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease.Turk J Med Sci. 2019 Jun 18;49(3):715-722. doi: 10.3906/sag-1808-67. Turk J Med Sci. 2019. PMID: 31023005 Free PMC article. Clinical Trial.
A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy.Eur Thyroid J. 2019 Jan;8(1):7-15. doi: 10.1159/000494837. Epub 2018 Dec 13. Eur Thyroid J. 2019. PMID: 30800636 Free PMC article.
Current and Emerging Treatment Strategies for Graves' Orbitopathy.Drugs. 2019 Feb;79(2):109-124. doi: 10.1007/s40265-018-1045-9. Drugs. 2019. PMID: 30659423 Review.
Effects of Selenium Supplementation on Graves' Disease: A Systematic Review and Meta-Analysis.Evid Based Complement Alternat Med. 2018 Sep 26;2018:3763565. doi: 10.1155/2018/3763565. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 30356415 Free PMC article. Review.
Selenium and Selenoproteins in Immune Mediated Thyroid Disorders.Diagnostics (Basel). 2018 Oct 4;8(4):70. doi: 10.3390/diagnostics8040070. Diagnostics (Basel). 2018. PMID: 30287753 Free PMC article. Review.